MCID: GLC008
MIFTS: 38

Glucose Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 14
Glucose Metabolism Disorders 41 69
Disorder of Glucose Metabolism 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4194
MeSH 41 D044882
NCIt 46 C53655
SNOMED-CT 64 126877002
UMLS 69 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and coronary artery anomaly. An important gene associated with Glucose Metabolism Disease is INS (Insulin), and among its related pathways/superpathways are Metabolism of proteins and Developmental Biology. The drugs Metformin and Clopidogrel have been mentioned in the context of this disorder. Related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 31.6 ACE ADIPOQ ALB CRP GCG IAPP
2 coronary artery anomaly 30.5 ACE ADIPOQ CRP INS
3 prader-willi syndrome 30.4 ADIPOQ GCG IGF1 INS LEP
4 arteries, anomalies of 30.0 ACE ADIPOQ ALB BACE1 CRP INS
5 body mass index quantitative trait locus 11 29.6 ADIPOQ CRP DPP4 GCG GIP IAPP
6 triosephosphate isomerase deficiency 10.9
7 malignant otitis externa 10.8 CRP INS
8 microvascular complications of diabetes 3 10.8 ACE ALB INS
9 nonalcoholic steatohepatitis 10.8 ADIPOQ INS LEP
10 mixed cell adenoma 10.8 IGF1 IRS1
11 hyporeninemic hypoaldosteronism 10.8 ACE REN
12 acquired generalized lipodystrophy 10.8 ADIPOQ LEP
13 familial partial lipodystrophy 10.8 INS LEP PPARG
14 orthostatic proteinuria 10.8 ACE ALB REN
15 fetal macrosomia 10.8 IGF1 INS LEP
16 3-hydroxyacyl-coa dehydrogenase deficiency 10.7 ADIPOQ INS PPARG
17 acanthosis nigricans 10.7 ADIPOQ INS LEP
18 anuria 10.7 ACE ALB REN
19 type 1 diabetes mellitus 15 10.7 GCG INS
20 acute insulin response 10.7 CRP GCG INS
21 hepatorenal syndrome 10.7 ACE ALB REN
22 renal hypertension 10.7 ACE ALB REN
23 protein-energy malnutrition 10.7 ALB IGF1 LEP
24 intermittent claudication 10.7 ACE ALB CRP
25 acute cystitis 10.7 ALB CRP IER3IP1
26 pyelonephritis 10.7 ACE ALB CRP
27 idiopathic edema 10.7 ACE ADIPOQ INS PPARG
28 dysentery 10.7 ALB CRP IER3IP1
29 inherited metabolic disorder 10.7 ADIPOQ CRP INS LEP
30 retinal vascular disease 10.7 ALB INS PSMD9
31 anovulation 10.7 IGF1 INS LEP
32 coronary heart disease 1 10.7 ACE ADIPOQ CRP INS
33 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.7 CRP INS LEP SLC2A4
34 uremia 10.7 ALB CRP INS LEP
35 severe pre-eclampsia 10.7 ADIPOQ ALB LEP
36 lutheran suppressor, x-linked 10.7 ADIPOQ INS IRS1 LEP
37 coronary stenosis 10.7 ACE ALB CRP
38 peripheral nervous system disease 10.7 INS PSMD9 TRPV1
39 immune system disease 10.7 ACE ALB CRP TRPV1
40 bladder disease 10.7 CRP IER3IP1 TRPV1
41 dumping syndrome 10.7 GCG GIP INS
42 lipodystrophy 10.7 ADIPOQ INS LEP PPARG
43 renal artery obstruction 10.7 ACE REN
44 microvascular complications of diabetes 5 10.7 ACE ALB IGF1 INS
45 hypertensive retinopathy 10.7 ACE ADIPOQ PSMD9 REN
46 secondary adrenal insufficiency 10.7 IGF1 INS
47 mental depression 10.7 DPP4 IER3IP1 PSMD9
48 nutritional deficiency disease 10.7 ALB CRP IGF1 LEP
49 interstitial nephritis 10.7 ACE ALB CRP REN
50 hypersensitivity reaction disease 10.7 ACE ALB TRPV1

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

MGI Mouse Phenotypes related to Glucose Metabolism Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 GIP IAPP ADIPOQ IGF1 ALB INS
2 growth/size/body region MP:0005378 10.28 DPP4 GIP IAPP ADIPOQ IGF1 INS
3 cardiovascular system MP:0005385 10.2 ACE ADIPOQ IGF1 INS CRP LEP
4 adipose tissue MP:0005375 10.18 ADIPOQ IGF1 INS ACE SLC5A2 PPARG
5 endocrine/exocrine gland MP:0005379 10.13 DPP4 ACE ADIPOQ IGF1 ALB LEP
6 immune system MP:0005387 10.13 ACE IAPP ADIPOQ IGF1 INS CRP
7 liver/biliary system MP:0005370 9.91 ACE ADIPOQ ALB INS LEP TRPV1
8 muscle MP:0005369 9.85 ADIPOQ IGF1 ALB INS BACE1 PPARG
9 neoplasm MP:0002006 9.5 ACE ADIPOQ IGF1 ALB LEP TRPV1
10 renal/urinary system MP:0005367 9.32 ADIPOQ IGF1 ALB INS ACE SLC5A2

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 4091 14219
2
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
3
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
4
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
5
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
6
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
7
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10238-21-8 3488
8
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 56180-94-0 441184
9
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
10
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21187-98-4 3475
11
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 160337-95-1
12
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 133107-64-9
13
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051 23994
14
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
15
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 204656-20-2 44147092
16
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
17
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850649-61-5 11450633
18
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
19
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 111025-46-8 4829
20
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
21
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
22
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
23
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
24
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
25
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
28
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
29
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
30
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 137862-53-4 60846
32
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
33
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
34
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
35
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1 51384-51-1, 37350-58-6 4171
36
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
37
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 40466924 5362032
38
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
39
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135062-02-1 65981
40
Nateglinide Approved, Investigational Phase 4,Phase 3,Phase 2 105816-04-4 60026
41
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
42
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 1 128-13-2 31401
43
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
44
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 842133-18-0
45
Oxymetazoline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 1491-59-4 4636
46
Phenylephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 59-42-7 6041
47
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
48
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
49
Glycerol Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 56-81-5 753
50
Amlodipine Approved Phase 4,Phase 3,Phase 1,Not Applicable 88150-42-9 2162

Interventional clinical trials:

(show top 50) (show all 10001)

# Name Status NCT ID Phase Drugs
1 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
2 Lactate and Hypoglycemia Unknown status NCT01387477 Phase 4 Lactate;Glucose
3 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
4 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
5 Randomized Trial Comparing Colesevelam vs. Ezetimibe Unknown status NCT02682680 Phase 4 Colesevelam;Ezetimibe
6 Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Unknown status NCT02624830 Phase 4 Sulfonylurea
7 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
8 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
9 Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes Unknown status NCT02526810 Phase 4 insulin lispro;Insulin Glargine
10 Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control Unknown status NCT02517242 Phase 4
11 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
12 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
13 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
14 Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes Unknown status NCT02449603 Phase 4 Exenatide;Biphasic insulin Aspart 30
15 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
16 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
17 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
18 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
19 Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound Unknown status NCT02274207 Phase 4
20 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
21 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
22 Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients Unknown status NCT02219750 Phase 4 switch twice-daily insulin
23 Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes Unknown status NCT02128815 Phase 4
24 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
25 Triple Therapy in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
26 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
27 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4 MET + Vildagliptin Group;MET + Glibenclamide Group
28 Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function Unknown status NCT01790308 Phase 4 CSII;Liraglutide
29 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
30 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4 Metformin;Metformin;Vildagliptin;Glimepiride
31 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
32 The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients Unknown status NCT01510509 Phase 4
33 Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use Unknown status NCT01500850 Phase 4 nph insulin;human insulin;Insulin Glargine;Insulin glulisine
34 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
35 Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study Unknown status NCT01417897 Phase 4 Insulin glulisine;Insulin aspart;Regular human insulin
36 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
37 Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
38 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4 Scilin®M30
39 Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes Unknown status NCT01281605 Phase 4
40 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
41 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
42 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
43 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
44 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
45 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
46 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
47 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
48 Cardiovascular Effects of Metformin on Obesity Unknown status NCT01910246 Phase 4 Metformin
49 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
50 Detemir Energy Expenditure Study Unknown status NCT00788840 Phase 4 Insulatard;Detemir

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

Publications for Glucose Metabolism Disease

Articles related to Glucose Metabolism Disease:

(show all 13)
# Title Authors Year
1
Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using (18)F-FDG-PET. ( 27763550 )
2016
2
Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. ( 24704332 )
2014
3
Relation of Periodontitis and Metabolic Syndrome with Gestational Glucose Metabolism Disorder. ( 23952077 )
2013
4
The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. ( 22345342 )
2012
5
Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. ( 22291689 )
2011
6
Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. ( 19909503 )
2009
7
Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. ( 20098572 )
2009
8
[Association of the calpain-10 gene polymorphism with glucose metabolism disorder in pregnant women]. ( 19570442 )
2009
9
Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. ( 18240540 )
2007
10
[Glucose metabolic disorders in relation with insulin resistance in pediatric age]. ( 15799852 )
2005
11
[Relationship between glucose metabolic disorders and expression of insulin receptor in posthepatitic cirrhosis hepatocyte and HBV DNA in pancreatic cells]. ( 15340556 )
2003
12
[Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids]. ( 11925670 )
2002
13
Evaluation of glucose metabolic disorder: insulin resistance and insulin receptors in critically ill children. ( 9275360 )
1996

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 ACE BACE1 DPP4 GCG GIP IAPP
2
Show member pathways
13.39 ADIPOQ IAPP INS IRS1 LEP PPARG
3
Show member pathways
12.66 ADIPOQ INS IRS1 LEP SLC2A4
4 12.4 ADIPOQ GCG INS IRS1 PPARG SLC2A4
5
Show member pathways
12.28 ADIPOQ IGF1 INS IRS1 LEP PPARG
6
Show member pathways
12.1 INS IRS1 LEP SLC2A4
7
Show member pathways
12.01 ADIPOQ IGF1 INS IRS1 PPARG
8
Show member pathways
11.98 IGF1 INS IRS1 SLC2A4
9 11.82 ADIPOQ IGF1 INS IRS1 LEP PPARG
10
Show member pathways
11.76 ADIPOQ INS IRS1 SLC2A4
11 11.72 ADIPOQ IGF1 INS LEP PPARG SLC2A4
12 11.6 ADIPOQ IRS1 LEP SLC2A4
13
Show member pathways
11.49 ACE DPP4 GCG GIP IGF1 INS
14 11.45 IRS1 LEP SLC2A4
15
Show member pathways
11.45 DPP4 GCG GIP LEP
16 11.42 INS IRS1 LEP
17 11.27 IGF1 INS IRS1
18 11.07 ADIPOQ LEP PPARG
19 10.7 ADIPOQ IRS1 LEP PPARG SLC2A4

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ACE ADIPOQ ALB CRP DPP4 GCG
2 endoplasmic reticulum lumen GO:0005788 9.55 ALB BACE1 GCG GIP INS
3 extracellular space GO:0005615 9.36 ACE ADIPOQ ALB CRP GCG GIP

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.89 ALB BACE1 IAPP IGF1 INS
2 positive regulation of protein kinase B signaling GO:0051897 9.84 IAPP INS IRS1 LEP
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 ADIPOQ IGF1 INS
4 positive regulation of MAPK cascade GO:0043410 9.81 IAPP IGF1 INS LEP
5 response to nutrient GO:0007584 9.8 ADIPOQ LEP PPARG
6 cellular response to insulin stimulus GO:0032869 9.78 ADIPOQ IRS1 PPARG SLC2A4
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 IGF1 INS LEP
8 glucose metabolic process GO:0006006 9.77 ADIPOQ INS LEP
9 regulation of insulin secretion GO:0050796 9.76 DPP4 GCG GIP LEP
10 response to nutrient levels GO:0031667 9.75 ADIPOQ GIP LEP
11 sensory perception of pain GO:0019233 9.74 GIP IAPP TRPV1
12 response to peptide hormone GO:0043434 9.73 GIP IRS1 TRPV1
13 regulation of blood pressure GO:0008217 9.73 ACE LEP PPARG REN
14 response to starvation GO:0042594 9.7 GCG GIP PPARG
15 regulation of receptor activity GO:0010469 9.7 ADIPOQ GCG GIP IAPP IGF1 INS
16 regulation of fat cell differentiation GO:0045598 9.65 LEP PPARG
17 response to lipid GO:0033993 9.65 GIP PPARG
18 insulin-like growth factor receptor signaling pathway GO:0048009 9.65 IGF1 IRS1
19 negative regulation of gluconeogenesis GO:0045721 9.64 ADIPOQ INS
20 angiotensin maturation GO:0002003 9.63 ACE REN
21 positive regulation of protein kinase A signaling GO:0010739 9.62 ADIPOQ IAPP
22 negative regulation of blood vessel diameter GO:0097756 9.61 CRP INS
23 negative regulation of lipid storage GO:0010888 9.61 CRP LEP
24 negative regulation of acute inflammatory response GO:0002674 9.58 INS PPARG
25 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 INS IRS1
26 bone mineralization involved in bone maturation GO:0035630 9.55 IGF1 LEP
27 amyloid-beta metabolic process GO:0050435 9.54 ACE BACE1 REN
28 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.5 ADIPOQ CRP PPARG
29 positive regulation of insulin receptor signaling pathway GO:0046628 9.43 INS IRS1 LEP
30 positive regulation of glucose import GO:0046326 9.26 ADIPOQ IGF1 INS IRS1
31 glucose homeostasis GO:0042593 9.1 ADIPOQ INS IRS1 LEP PPARG SLC2A4
32 positive regulation of cell proliferation GO:0008284 10.04 DPP4 IGF1 INS IRS1 LEP

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 ADIPOQ ALB CRP DPP4 GCG IAPP
2 receptor binding GO:0005102 9.73 ADIPOQ DPP4 GCG IAPP LEP REN
3 endopeptidase activity GO:0004175 9.58 ACE BACE1 REN
4 drug binding GO:0008144 9.54 ACE ALB PPARG
5 insulin receptor binding GO:0005158 9.5 IGF1 INS IRS1
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS IRS1 REN
7 hormone activity GO:0005179 9.17 ADIPOQ GCG GIP IAPP IGF1 INS

Sources for Glucose Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....